CHAMGAP
VERIFIEDPassed the Codex final verification and publication gate. Evidence-verification cutoff: 2026-08-26. AI was used for research and drafting; the existence of all 1 cited sources was verified at the original page, followed by blind grading, adversarial audit, and build validation. Methodology v0.8.
Verdict No. 2967 · Search date 2026-08-26 · Methodology v0.8

Bacillus coagulans IDCC 1201, 5 billion CFU/day,
does it really help with Improved polysomnographic sleep efficiency after four weeks in adults with sleep disturbance?

30-Second Summary
C
Evidence Grade C · 50 · Safety caution
Sleep efficiency improved, but the evidence is one manufacturer-funded four-week trial registered after completion
No significant adverse events or intervention-related effects were reported over four weeks. Systolic-pressure change differed at P=.019 but remained clinically normal; four weeks is too short to establish long-term safety.
What the
research shows
Grade C. In the per-protocol population of 78 from an 80-person trial, sleep-efficiency change was +13.71±21.14 points versus -0.15±13.35, a +13.86-point difference (P=.002); no confidence interval was reported. The trial was registered seven months after completion, baseline sleep efficiency differed, and the manufacturer fully funded it.
What the
ads claim
The finding is limited to IDCC 1201, 5 billion CFU one hour before bed, for four weeks. It does not establish a class effect or treatment of diagnosed insomnia.
*

Useful facts when choosing a product

  • Sleep efficiency is the proportion of time in bed actually spent asleep.
  • Severe insomnia and diagnosed sleep disorders were excluded.
  • Baseline imbalance remains important even though adjusted analysis was positive.
Gap Measurement · Verdict 2967 · C 50
What advertising claims
What independent, higher-quality research supports
△ GAP
01

What the research actually shows

The double-blind placebo-controlled trial randomized 80 adults, 40 per arm, and analyzed 39 per arm in the per-protocol efficacy set. Enrollment began February 3, 2025 and the trial ended July 2, 2025, but CRIS registration KCT0011568 occurred February 2, 2026, after completion. Ildong Bioscience funded the study and supplied active and placebo capsules; Hayoung Kim, Jinho Lee, Won Yeong Bang, Han Bin Lee, and Jin Seok Moon were employees. The paper states that the company had no role in recruitment, collection, outcome assessment, or statistical analysis.

02

Why this is classified as C (50)

A positive PSG result is limited by one manufacturer trial, an 80-person per-protocol analysis, four weeks, and retrospective registration, giving C with 50 points.

Counterpoint. Subjective insomnia relief and PSG efficiency are different endpoints, and strain-specific results vary.

Rejudgment record. Cross-check applied — Positive PSG sleep-efficiency and adjusted results, limited by manufacturer-only evidence, retrospective registration, and a small short per-protocol analysis

Scoring profile behind this grade
EndpointSSurrogate marker - laboratory or imaging measures
ReplicationR1Single confirmatory trial
IndependenceI0Evidence comes only from manufacturer studies
Effect sizeE+Meets the clinically important threshold

The scoring table and the verdict agree (C).

Sub-claim grades by effect

This ingredient is marketed for several effects. A single overall grade blends strong and weak claims together, so each effect is graded separately here. The overall grade reflects the strongest disconfirming or core claim.

Effect (sub-claim)GradeBasis
Improved four-week PSG sleep efficiencyCAdjusted analysis was also positive, but this is one short manufacturer trial.

Cross-check — AI research and Codex final gate

AI was used for research and drafting. Blind grading, adversarial audit, and the methodology boundary rules were then reapplied before Codex performed the final evidence, grade, copy, and build checks. If a grade cannot be narrowed, both evidence positions and their reasons are published.
03

Evidence Table

StudyDesignSampleFundingEndpointResultWeight
Study 1Double-blind randomized placebo-controlled PSG trial39Ildong Bioscience funding and active/placebo products; five employee authorsChange from baseline to week 4 in PSG sleep efficiency+13.71±21.14 vs -0.15±13.35 points; difference +13.86 points, P=.002; baseline-adjusted P=.015; CI not reportedSingle retrospectively registered manufacturer trial
§

Receipt — 1 References

All 1 cited sources were verified for existence at the original page (as of 2026-08-26).

Kim H, et al. Efficacy and Safety of Bacillus coagulans IDCC 1201 for Sleep Improvement in Adults with Sleep Disturbance. Nutrients. 2026;18:1525. PMID: 42196985.
checked
Research and draft: AI used · Cross-check: blind grading and adversarial audit
Final verification and publication gate: Codex · Verification cutoff: 2026-08-26 · Corrections: none

Cite this verdict

Benefit of Bacillus coagulans IDCC 1201 for Four-Week Sleep Efficiency Evidence Grade C card
[Chamgap] Benefit of Bacillus coagulans IDCC 1201 for Four-Week Sleep Efficiency — Evidence Grade C·50. 1 cited sources checked. Source: https://chamgap.com/en/verdicts/sleep/bacillus-coagulans-idcc-1201-sleep-efficiency/ · CC BY 4.0

CC BY 4.0 — free to use with attribution; do not distort grades, numbers, or verdict meaning.

!

What this document does and does not do

Chamgap is an information source. It reports what research has and has not confirmed; it does not tell readers what to take or buy. That decision belongs to readers and, when needed, medical or legal professionals. This verdict reflects literature available up to the search date and may change as new research appears. Nothing here is medical advice.